Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy-Reply

Neil M Bressler^{1

2}

Affiliations

Comment

Neil M Bressler. JAMA Ophthalmol. 2021.

. 2021 Jun 1;139(6):678-679.

doi: 10.1001/jamaophthalmol.2021.1043.

Neil M Bressler^{1

2}

¹ Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Editor, JAMA Ophthalmology.

No abstract available

Comment on

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM. Woo SJ, et al. JAMA Ophthalmol. 2021 Jan 1;139(1):68-76. doi: 10.1001/jamaophthalmol.2020.5053. JAMA Ophthalmol. 2021. PMID: 33211076 Free PMC article. Clinical Trial.
Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy.
Sharma A, Kumar N, Parachuri N. Sharma A, et al. JAMA Ophthalmol. 2021 Jun 1;139(6):677-679. doi: 10.1001/jamaophthalmol.2021.1037. JAMA Ophthalmol. 2021. PMID: 33914017 No abstract available.